Pienta KJ - Search Results

1

Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.

Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Loberg RD, et al. Among authors: pienta kj. J Clin Oncol. 2005 Nov 10;23(32):8232-41. doi: 10.1200/JCO.2005.03.0841. J Clin Oncol. 2005. PMID: 16278478 Review.

2

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.

Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE. Pienta KJ, et al. J Clin Oncol. 1994 Oct;12(10):2005-12. doi: 10.1200/JCO.1994.12.10.2005. J Clin Oncol. 1994. PMID: 7523606 Clinical Trial.

3

A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostate.

Pienta KJ, Redman BG, Esper PS, Flaherty LE. Pienta KJ, et al. Am J Clin Oncol. 1996 Oct;19(5):500-3. doi: 10.1097/00000421-199610000-00014. Am J Clin Oncol. 1996. PMID: 8823479 Clinical Trial.

4

Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate.

Pienta KJ, Esper PS, Zwas F, Krzeminski R, Flaherty LE. Pienta KJ, et al. Am J Clin Oncol. 1997 Feb;20(1):36-9. doi: 10.1097/00000421-199702000-00008. Am J Clin Oncol. 1997. PMID: 9020285 Clinical Trial.

5

The use of prostate-specific antigen as a surrogate end point in the treatment of patients with hormone refractory prostate cancer.

Smith DC, Pienta KJ. Smith DC, et al. Among authors: pienta kj. Urol Clin North Am. 1997 May;24(2):433-7. doi: 10.1016/s0094-0143(05)70390-6. Urol Clin North Am. 1997. PMID: 9126241

6

Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.

Pienta KJ, Smith DC. Pienta KJ, et al. Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-72-S15-77. Semin Oncol. 1997. PMID: 9346227 Clinical Trial.

7

Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line.

Lehr JE, Pienta KJ. Lehr JE, et al. Among authors: pienta kj. J Natl Cancer Inst. 1998 Jan 21;90(2):118-23. doi: 10.1093/jnci/90.2.118. J Natl Cancer Inst. 1998. PMID: 9450571

8

Development of doxorubicin resistant rat prostate cancer cell lines.

Replogle-Schwab TS, Schwab ED, Pienta KJ. Replogle-Schwab TS, et al. Among authors: pienta kj. Anticancer Res. 1997 Nov-Dec;17(6D):4535-8. Anticancer Res. 1997. PMID: 9494564

9

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.

Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Smith DC, et al. Among authors: pienta kj. J Clin Oncol. 1998 May;16(5):1835-43. doi: 10.1200/JCO.1998.16.5.1835. J Clin Oncol. 1998. PMID: 9586898 Clinical Trial.

10

The effect of amiloride on the metastatic properties of prostate cancer in the Dunning rat model.

Pilat MJ, Lehr JE, Quigley MM, Pienta KJ. Pilat MJ, et al. Among authors: pienta kj. Oncol Rep. 1998 Jul-Aug;5(4):889-92. doi: 10.3892/or.5.4.889. Oncol Rep. 1998. PMID: 9625839

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

652 results

Search Page

Filters